Zacks Investment Research upgraded shares of Cytomedix, Inc (CMXI) from NEUTRAL to OUTPERFORM on April 28, 2014, with a target price of $1.50.
Last week we attended the Symposium on Advanced Wound Care (SAWC) in Orlando, FL. We spent over three hours on the massive exhibit hall floor, having conversations with various companies and wound care professionals. Almost every major advanced product for the treatment of chronic wounds was there on display, including Dermagraft , Apligraf , Epifix , Grafix , Oasis Wound Matrix, Regranex , MatriStem , and AutoloGel . In our report we highly Cytomedix data from SAWC and outline our belief that now is a good time to establish a position in the stock. We believe the shares are fairly-value at $1.50, and this includes no contribution from the Aldagen pipeline or the ongoing RECOVER-Stroke trial with ALD-401 that is expected to report data very soon. Our rating is now Buy'.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Cytomedix, Inc (CMXI),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment